Matinas BioPharma gets 2027 window to restore NYSE American listing compliance
At a glance
- $MTNB today−7.69%last $0.86
- Vs industry peers−6.49 pts6-peer median −1.20% · far behind
- Since Sep 4−68.7%from the first trade after the story
- 52-week range6.0% above low$0.81 – $18.03
- Sector scannerCalmHealth Care
Nothing reported about matinas biopharma across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: Drugmakers live and die by pipelines — what is in late-stage trials matters more than this quarter's sales.
- How the stock is trading: $MTNB -7.69% in the latest session.
- Timing: It was published after the close, so the day's move was settled before the story existed. The next session is the first that could react.
Where the stock stands
Matinas Biopharma ($MTNB) fell 7.69% to $0.86 in the latest session. Over the past month it is down 48.5%. It now sits 95% under the 52-week high of $18.03 and 6.0% above the year's low of $0.81, close to the bottom of its range. The year's high was 22.3 times its low, which makes double-digit swings fairly routine here.
How much coverage it is getting
Nothing new on Matinas Biopharma has come through Wook's feeds in the last 30 days, so this is still the most recent story on it.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
What to watch next
For the company's side of it, read its latest SEC filings on the $MTNB page. A US company has to report material news on an 8-K, usually within four business days; foreign issuers use a 6-K. Where several outlets agree is usually the news; where they differ is the angle. Wook AI, at the top of the page, can work out how far $MTNB is from its high or compare this week's coverage with earlier weeks.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Seeking Alpha published this on September 4, 2026. $MTNB has moved -68.66% ($2.73 to $0.86). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
